Rocbrutinib: First Approval

<p dir="ltr"><b>Funding </b>The preparation of this review was not supported by any external funding.</p><p dir="ltr"><b>Declarations</b></p><p dir="ltr"><b>Authorship and Conflict of interest </b>During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy.

S. Fung is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.</p><p dir="ltr">Additional information about this Adis Drug Review can be found <a href="springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews" target="_blank"><b>here</b></a>.</p><p dir="ltr"><b>Abstract</b></p><p dir="ltr">Rocbrutinib (麓可达; LP-168) is a fourth generation Bruton's tyrosine kinase (BTK) inhibitor with both covalent and non-covalent modes of binding, which allow it to inhibit both wildtype as well as mutant variants of BTK.